Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

39.19 -0.03 (-0.07%)
Streaming Delayed Price Updated: 11:34 AM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 337,050
Open 39.22
Bid (Size) 39.17 (400)
Ask (Size) 39.20 (300)
Prev. Close 39.22
Today's Range 39.10 - 39.34
52wk Range 25.18 - 41.24
Shares Outstanding 388,132,400
Dividend Yield 2.25%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 15.6% over... 
Via StockStory
Topics Stocks
News headline image
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
From Royalty Pharma plc
Via GlobeNewswire

Performance

YTD
+52.0%
+52.0%
1 Month
-2.1%
-2.1%
3 Month
+11.2%
+11.2%
6 Month
+8.8%
+8.8%
1 Year
+54.8%
+54.8%

More News

Read More
News headline image
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shows Strong Technical Setup for a Breakout ↗
Via Chartmill
News headline image
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
3 Mid-Cap Stocks That Concern Us
Via StockStory
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
Via Investor's Business Daily
News headline image
3 Value Stocks with Warning Signs
Via StockStory
Topics Supply Chain
News headline image
3 Low-Volatility Stocks We Find Risky
Via StockStory
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?
Via StockStory
Topics Stocks Supply Chain
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
Via MarketMinute
Topics Intellectual Property
News headline image
Royalty Pharma (NASDAQ:RPRX) Q3 2025 Earnings Beat Estimates and Raise Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗
Via Benzinga
Topics Economy
News headline image
Royalty Pharma Reports Third Quarter 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
What To Expect From Royalty Pharma’s (RPRX) Q3 Earnings
Via StockStory
Topics Artificial Intelligence
News headline image
ROYALTY PHARMA PLC-CL A (RPRX) Shows Strong Technicals and a High-Quality Breakout Setup ↗
Via Chartmill
News headline image
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗
Via MarketBeat
News headline image
2 Reasons to Avoid RPRX and 1 Stock to Buy Instead
Via StockStory
Topics Government Stocks Supply Chain
News headline image
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data ↗
Via MarketBeat
News headline image
Royalty Pharma Declares Fourth Quarter 2025 Dividend
From Royalty Pharma plc
Via GlobeNewswire

Frequently Asked Questions

Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
The current price of Royalty Pharma plc - Class A Ordinary Shares is 39.19
When was Royalty Pharma plc - Class A Ordinary Shares last traded?
The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 12/29/25 11:34 AM ET
What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 15.21B
How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
Royalty Pharma plc - Class A Ordinary Shares has 15B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.